Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Clearside Biomedi 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 USA

www.clearsidebio.com P: 678-270-3631 F: 678-270-4033

Description:

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.

Key Statistics

Overview:

Market Capitalization, $K 100,126
Enterprise Value, $K 71,206
Shares Outstanding, K 74,721
Annual Sales, $ 8,230 K
Annual Net Income, $ -32,490 K
Last Quarter Sales, $ 6,340 K
Last Quarter Net Income, $ -4,830 K
EBIT, $ -24,850 K
EBITDA, $ -24,780 K
60-Month Beta 2.29
% of Insider Shareholders 9.80%
% of Institutional Shareholders 18.75%
Float, K 67,398
% Float 90.20%
Short Volume Ratio 0.48

Growth:

1-Year Return 20.56%
3-Year Return -56.35%
5-Year Return 9.84%
5-Year Revenue Growth 27,333.33%
5-Year Earnings Growth 80.30%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 03/12/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -0.53
EPS Growth vs. Prev Qtr 46.67%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CLSD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -85.31%
Profit Margin % -394.78%
Debt/Equity 0.00
Price/Sales 12.44
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.25
Interest Coverage -1.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar